SCM
ELDN icon

Stonepine Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Stonepine Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$108K Sell
35,000
-858,100
-96% -$2.02M 0.04% 79
2025
Q4 		$1.35M Buy
+893,100
New +$2.12M 0.98% 30
2021
Q1 		– Sell
-167,333
Closed -$2.58M – 31
2020
Q4 		$2.58M Buy
+167,333
New +$3.19M 1.97% 16

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Stonepine Capital Management's ELDN Position: Q1 2026 in Review

Stonepine Capital Management reduced its Eledon Pharmaceuticals (ELDN) stake by 96% in Q1 2026, selling an estimated $2.02M and leaving 35,000 shares worth $108K. The position accounts for 0.04% of the portfolio, ranked #79.

Stonepine Capital Management first reported a position in ELDN in Q4 2020 and has held it in 3 quarters since. The position peaked at $2.58M in Q4 2020. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Stonepine Capital Management held 35,000 shares of Eledon Pharmaceuticals worth $108K as of Q1 2026.
  • Stonepine Capital Management sold 858,100 Eledon Pharmaceuticals shares in Q1 2026, an estimated $2.02M.
  • Eledon Pharmaceuticals made up 0.04% of Stonepine Capital Management's portfolio in Q1 2026, its #79 holding.
  • Stonepine Capital Management first reported a position in Eledon Pharmaceuticals in Q4 2020 and has held it in 3 quarters since.
  • Stonepine Capital Management's Eledon Pharmaceuticals position peaked at $2.58M in Q4 2020.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.